OncoSec Medical logo

OncoSec Medical(OTC) ONCS

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)-100%
5 Year-100%
1 Year+0%
1 Month+0%
N/A
OncoSec Medical last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-09
OncoSec Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-10-02
1 month+0%USD 0.002026-09-03
3 month+0%USD 0.002026-07-01
Year to date+0%USD 0.002025-12-30
1 year+0%USD 0.002025-10-09
3 year-99.67%USD 0.002023-10-10
5 year-100%USD 40.922021-10-08
Since inception-100%USD 9.622010-04-07

OncoSec Medical Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$30.14M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Dec 11, 2020

ONCS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About OncoSec Medical

OncoSec Medical Incorporated is an immuno-oncology firm focused on developing DNA-based treatments for cancer. The company aims to activate and enhance the body's immune response through innovative therapies administered directly into tumors.

Products and Services
  • KEYNOTE-695: Phase 2 trials for advanced melanoma
  • TAVO therapies: Combination treatments for various cancers
  • Research partnerships: Collaborations with Merck & Co. and Duke University
Growth Outlook
  • Potential for significant market impact with advanced melanoma treatments
  • Innovative TAVO therapies targeting multiple cancer types
  • Strategic alliances may enhance research and development capabilities
Financial Highlights
  • Recent quarterly net income of -$6.86 million
  • Cash and cash equivalents of $3.68 million as of January 31, 2023
  • Current ratio of 2.30 indicates strong short-term financial health
OncoSec Medical Incorporated has positioned itself in the biotechnology sector with a focus on innovative cancer therapies. The company's diverse product portfolio includes several promising treatments currently in various stages of clinical trials. The strategic partnerships with established firms like Merck & Co. and academic institutions like Duke University may provide valuable resources and expertise, potentially accelerating the development of its therapies. Financially, the company has faced challenges, as indicated by recent net income figures, but maintains a solid current ratio, suggesting adequate liquidity to meet short-term obligations. The ongoing research and development efforts, combined with a strong pipeline of therapies, may present opportunities for future growth and market presence in the competitive landscape of cancer treatment.
AI Generated • Oct 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

41

CEO

Robert H. Arch, PhD

Website

www.oncosec.com

Headquarters

Pennington, NJ 08534, US

ONCS Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-154.68%

Return on Capital

-301.08%

Return on Assets

-156.23%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$32.65M

EBITDA

-$31.73M

Operating Cash Flow

-$24.99M

Capital Expenditure

-$244.86K

Free Cash Flow

-$25.24M

Cash & ST Invst.

$3.68M

Total Debt

$3.46M

OncoSec Medical Performance Analysis

OncoSec Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-07-31USD 0N/A
OncoSec Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-04-30N/A
Q42022-07-31N/A
Q12022-10-31N/A
Q22023-01-31N/A
OncoSec Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-07-31USD -19.13N/A
OncoSec Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-04-3037.0%
Q42022-07-31-31.8%
Q12022-10-31-7.2%
Q22023-01-31-5278.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2023YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

40

N/A

Net Income

-$6.86M

+30.8%

EBITDA

-$6.81M

+29.0%

Quarterly Fundamentals

Name
Q2 2023YOY CHG

Total Cash

$3.68M

-85.4%

Total Debt

$3.46M

-44.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$2.13M

-54.8%

Short Term Debt

$1.34M

-12.8%

Return on Assets

-1.56%

N/A

Return on Invested Capital

-2.43%

N/A

Free Cash Flow

-$6.61M

+34.0%

Operating Cash Flow

-$6.61M

+34.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ONCTOncternal Therapeutics, Inc.
$0.53-24.12%
NBSENeuBase Therapeutics, Inc.
$0.38-1.56%
SAVAWCassava Sciences, Inc. Warrant
$0.03+0.00%
ZIVOZIVO Bioscience, Inc.
$6.51+22.83%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$14.72-6.48%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$127.57-0.65%
NOKNokia
$9.86-0.40%

Questions About ONCS

What is the current price of OncoSec Medical?

OncoSec Medical is trading at N/A per share.

What is the 52-week range for OncoSec Medical?

Over the past 52 weeks, OncoSec Medical has traded between N/A and N/A.

How much debt does OncoSec Medical have?

As of the most recent reporting period, OncoSec Medical reported total debt of $6.17M.

How much cash does OncoSec Medical have on hand?

OncoSec Medical reported $12.30M in cash and cash equivalents in its most recent financial results.

What is OncoSec Medical’s dividend yield?

OncoSec Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services